Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern
April 25, 2022 09:30 ET
|
Sorrento Therapeutics, Inc.
FDA granted IND clearance today for STI-9167 (Intravenous COVISHIELD™) for a Phase 1 safety and pharmacokinetic study in healthy volunteers.Initial trials are expected to be followed by a...
Dr. Henry Ji, Sorrento Therapeutics’ Chairman and CEO and Scilex Holding Company’s Executive Chairman, to Present at the B. Riley Securities’ 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022)
April 25, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO and PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and...
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill
April 12, 2022 21:15 ET
|
Sorrento Therapeutics, Inc.
PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE,...
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022
April 04, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
ZTlido 53% year-over-year preliminary unaudited gross sales in March 2022Select payor accounts representing approximately 200 million of the over 300 million covered lives across the United States ...
Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
March 31, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Abivertinib is a novel oral small molecule tyrosine kinase inhibitor that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) as well as Bruton's tyrosine kinase (BTK)...
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp I
March 25, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial...
Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants
March 20, 2022 17:26 ET
|
Sorrento Therapeutics, Inc.
Sorrento scientists have perfected the expression of the spike protein to potentially improve the safety profile of the COVID-19 mRNA vaccines by incorporating a furin cleavage site mutation to...
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity
March 18, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
SP-102 (SEMDEXA™), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy), experienced a rapid onset of pain relief, measured by Numeric...
Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I
March 17, 2022 15:35 ET
|
Sorrento Therapeutics, Inc.
Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds before...
Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure
March 02, 2022 11:37 ET
|
Sorrento Therapeutics, Inc.
STI-9199 neutralizing antibody (nAb) nasal drops prevent productive infections when given to animals 24 hours before they are exposed to COVID.This intranasal STI-9199 may potentially give the option...